89Bio Inc
Change company Symbol lookup
Select an option...
ETNB 89Bio Inc
ETN Eaton Corporation PLC
AUD Audacy Inc
ETH Ethan Allen Interiors Inc
ETAC E.Merge Technology Acquisition Corp
ET Energy Transfer LP
ESXB Community Bankers Trust Corp
WWW Wolverine World Wide Inc
FB Facebook Inc
F Ford Motor Co
Go

Health Care : Biotechnology | Small Cap Value
Company profile

89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH). FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism.

Closing Price
$18.67
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
88,608
0

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.